Assessing the Candidacy of March1 as a Therapeutic Target for Treatment of Asthma
Technical Report,01 Jun 2018,31 May 2019
University of California San Francisco United States
Pagination or Media Count:
Asthma is a serious economic and health concern in the United States. Although multiple controlling medications exist, many of them exert significant side effects while treatment is not sufficiently achieved. Therefore, development of better drugs by identifying new molecular targets is in urgent need. The purpose of this project to is to assess the candidacy of a molecule named MARCH1 as a novel therapeutic target for treatment of asthma. By using a mouse model of asthma, we found that MARCH1 plays a significant role in evoking type 2 T helper cell-driven inflammation in asthmatic airways. We also found that MARCH1activity can be inhibited by the membrane trans-passing domain of CD83 involving the tyrosine-containing helical face. These findings suggest that one could develop a small molecule inhibitor of MARCH1 by exploiting the CD83 transmembrane domain and utilize this inhibitor as a therapeutic for treatment of asthma.
- Medicine and Medical Research